Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. (Q48132256)

9 February 2018

title

Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. (English)

1 reference

9 February 2018

1 reference

1 reference

7

1 reference

9 February 2018

author name string

Mogi M

1

1 reference

9 February 2018

Togari A

2

1 reference

9 February 2018

Kondo T

3

1 reference

9 February 2018

Mizuno Y

4

1 reference

9 February 2018

Komure O

5

1 reference

9 February 2018

Kuno S

6

1 reference

9 February 2018

Nagatsu T

8

1 reference

9 February 2018

language of work or name

English

0 references

publication date

1 July 1999

1 reference

9 February 2018

published in

Neuroscience Letters

1 reference

9 February 2018

volume

270

1 reference

9 February 2018

page(s)

45-48

1 reference

9 February 2018

issue

1

1 reference

9 February 2018

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

The low concordance rate for Parkinson's disease in twins: a possible explanation

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Prevention of dopaminergic neuron death by adeno-associated virus vector-mediated GDNF gene transfer in rat mesencephalic cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Functional recovery in parkinsonian monkeys treated with GDNF

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Neurotrophin-4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Coexpression of neurotrophins and their receptors in neurons of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Neurotrophic factors: from molecule to man.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

NT-3, BDNF, and NGF in the developing rat nervous system: Parallel as well as reciprocal patterns of expression

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1beta and nerve growth factor in the striatum.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Fetal nigral transplantation as a therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

An enzyme-linked immunoassay for nerve growth factor (NGF): a tool for studying regulatory mechanisms involved in NGF production in brain and in peripheral tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900463-2

7 January 2021

10.1016/S0304-3940(99)00463-2

Identifiers

DOI

1 reference

9 February 2018

PubMed ID

10454142

1 reference

9 February 2018